Sub Banner Image

Pfizer's Core Drugs Offset COVID Revenue Drop, Lifts 2025 Profit Outlook Despite Tariffs

Market Impact

Vandana Singh

·

November 4, 2025

·

Benzinga

Pfizer beat Q3 estimates with 87 cents EPS, raised 2025 profit guidance, as Eliquis and Vyndaqel growth offset declining COVID product sales.

read more

More from

Benzinga

More

Market Impact

Articles

Trending News

Enjoy premium content in your inbox.

You're in! Check your email to learn more.
Oops! Something went wrong while submitting the form.